# OnCo record nct05882058 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05882058/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05882058", "NCT05882058" ;
  schema:name "DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers"@en ;
  schema:description "A phase 2 trial of BI 764532, dose 1 in small-cell lung cancer and neuroendocrine tumours, run by Boehringer Ingelheim, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05882058/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05882058> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2023-10-13" ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/neuroendocrine/>, <https://onco.cc/cancers/extrapulmonary-nec/>, <https://onco.cc/cancers/extensive-stage-sclc/> ;
  onco:drugs <https://onco.cc/drugs/obrixtamig/> ;
  onco:companies <https://onco.cc/companies/boehringer-ingelheim/> .